Oncology and Hematology - Prova Education

33-48 of 189

Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
MinuteCE®
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Michiel van de Sande, MD, PhD
1.00 program credit
- Michiel van de Sande, MD, PhD
1.00 program credit
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
All Sides of the Joint: Integrated TGCT Care Across Specialties
All Sides of the Joint: Integrated TGCT Care Across Specialties
MinuteCE®
All Sides of the Joint: Integrated TGCT Care Across Specialties
A.J. Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
- Chelsea Cole, MD
1.00 program credit
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
MinuteCE®
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
MinuteCE®
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
MinuteCE®
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
MinuteCE®
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
MinuteCE®
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
A.J. Gelderblom, MD, PhD; Chelsea Cole, MD
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Chelsea Cole, MD
1.00 program credit
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
MinuteCE®
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
A.J. Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
1.00 program credit
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH; Kathleen Moore, MD, MS
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen Moore, MD, MS
0.50 program credits
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen Moore, MD, MS; Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
- Kathleen Moore, MD, MS
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
MOA: CDH6-Targeted Antibody-Drug Conjugates
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
Kathleen Moore, MD, MS
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits

3/8